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Breathlessness services as a new
model of support for patients with
respiratory disease
Claudia Bausewein1, Michaela Schunk1, Philipp Schumacher1,
Julika Dittmer1, Anna Bolzani1 and Sara Booth2
Abstract
The complexity of breathlessness in advanced disease requires a diversity of measures ideally tailored to the
individual patient needs. ‘Breathlessness services’ have been systematically developed and tested to provide
specific interventions and support for patients and their carers. The aim of this article is (1) to identify and
describe components of breathlessness services and (2) to describe the clinical model of one specific service in
more detail. This article is based on a systematic review evaluating randomized controlled trials (RCTs) and
quasi-RCTs which examine the effectiveness of services aiming to improve breathlessness of patients with
advanced disease. The Munich Breathlessness Service (MBS) is described in detail as an example of a recently
set-up specialist service. Five service models were identified which were tested in six RCTs. Services varied
regarding structure and composition with face-to-face meetings, some with additional telephone contacts.
Service duration was median 6 weeks (range 2–12 weeks). Involved professions were nurses, various therapists
and, in two models, also physicians. The breathing–thinking–functioning model was targeted by various service
components. The MBS is run by a multi-professional team mainly with physicians and physiotherapists. Patients
are seen weekly over 5–6 weeks with an individualized management plan. Breathlessness services are a new
model for patients with advanced disease integrating symptom management and early access to palliative care.
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Introduction
Breathlessness is one of the most distressing symp-
toms in advanced disease affecting patients with pri-
mary and secondary cancer, lung diseases (e.g.
chronic obstructive pulmonary disease (COPD), pul-
monary hypertension, cystic fibrosis, interstitial lung
disease (ILD)), congestive heart failure (CHF) or
motor neuron disease (MND)).1–3 Breathlessness is
a unique and subjective experience to the individual
reflecting the patients’ perspective based on the daily
experience, whereas the medical term ‘dyspnoea’ is
focusing more on the clinical sign of an underlying
condition.2,4 Recently, it has been proposed to define
breathlessness as a chronic syndrome that persists
despite optimal treatment of the underlying pathophy-
siology and that results in disability.5
As breathlessness affects individuals in different
ways and in different dimensions, Booth and Spathis
have proposed the breathing–thinking–functioning
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model as a clinical model to conceptualize the three
predominant cognitive and behavioural reactions to
breathlessness that, by causing vicious cycles, worsen
and maintain the symptom.6,7
 Breathing domain: Breathlessness causes dys-
functional breathing patterns with an increased
respiratory rate, the need for the use of acces-
sory muscles and dynamic hyperinflation, lead-
ing to inefficient breathing and increased work
of breathing.
 Thinking domain: Misconceptions and paying
too much attention to the sensation of breath-
lessness such as memories of past or negative
experiences lead to anxiety, distress, feelings of
panic and thoughts about dying.
 Functioning domain: People suffering from
breathlessness often reduce their physical activ-
ity, leading to self-isolation and the need formore
help from others and also leading to decondition-
ing of limb, chest wall and accessory muscles.
Management of breathlessness is challenging and
comprises various non-pharmacological and pharma-
cological measures. Optimal management of the
underlying disease is always the first step. However,
there is an inconsistent relationship between pathol-
ogy and breathlessness perception, explaining why
optimizing disease management alone does not guar-
antee good symptom control.6
There are a wide range of non-pharmacological
interventions with various strengths of evidence. Pul-
monary rehabilitation is supported by strong evidence
and reduces breathlessness significantly.8 Cognitive
behavioural therapy also has an effect on breathless-
ness, anxiety and depression.9 Handheld fans have
been tested as well as rollators or various forms of
breathing techniques such as ‘pursed lip breathing’
and ‘abdominal breathing.’10 For pharmacological
management, opioids are the drugs of choice for
patients with severe breathlessness and breathlessness
at rest with good evidence.11,12 Although benzodiaze-
pines are frequently used, the supporting evidence is
very limited.13
Overall, one single intervention used alone is
unlikely to palliate breathlessness effectively.14 This
complex symptom is more likely to require a complex
intervention with a diversity of skills, personal attri-
butes and strengths within team members.15 A num-
ber of measures are necessary that are ideally tailored
to the individual needs of the patient and provided
in one overarching concept. Over recent years, the
so-called breathlessness services have been system-
atically developed and tested to provide specific
interventions and support for patients, breathless from
any advanced disease and their carers.16
The aim of this article is (1) to identify and describe
components of services identified in the studies test-
ing the effectiveness of breathlessness services which
aim to improve the symptom in patients with
advanced disease and (2) to describe the clinical
model of one specific service in more detail.
Methods
1. The description of service components is part of
a wider systematic review currently being con-
ducted focussing on non-pharmacological inter-
ventions in breathlessness. One part of the
review is evaluating randomized controlled
trials (RCTs) and quasi-RCTs which examine
the effectiveness of services (as complex inter-
ventions) which aim to improve breathlessness
of patients with advanced disease. We included
studies with adults suffering from advanced dis-
ease of any aetiology associated with a high
prevalence of breathlessness. These were
 Advanced local or metastatic cancer
 Severe COPD with a forced expiratory vol-
ume in one second predicted of <50%
 Pulmonary hypertension with World
Health Organization class  level III
 Congestive heart failure (CHF) with the
New York Heart Association stage III/IV
 ILD
 MND/Amyotrophic lateral sclerosis (ALS)
The outcome of interest was any measure of
breathlessness assessed by specific validated
breathlessness questionnaires or by other self-
reported methods.
We searched the main electronic databases
from the Cochrane Library (Cochrane Database
of Systematic Reviews and Cochrane Central
Register of Controlled Trials), MEDLINE,
EMBASE, PsycINFO and CINAHL using
search terms relating to dyspnoea and breath-
lessness, underlying diseases and the Cochrane
Highly Sensitive Search Strategy for identify-
ing randomized trials. All titles and abstracts
retrieved by the search were independently
screened by two reviewers to identify all trials
that may be eligible for the review.
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2. The Munich Breathlessness Service (MBS) is
described in detail as an example of a recently
set-up specialist service targeting breathless-
ness in advanced disease. It was set up in
2014 building on the results of previous studies
and the London Breathlessness Support Ser-
vice (BSS).17
Results
We identified five service models tested in six RCTs
published in 10 papers.17–26
Structure and composition of services
All services were delivered face-to-face at home or in
the clinic in combination with intermittent telephone
calls. Bredin and Higginson only used face-to-face
meetings,17,19 the other services also integrated one
to six telephone contacts. The number of face-to-face
meetings varied from one26 to eight.19 The contacts
with the patients took place either in the clinic
only19,24 or in the patient’s home20,22 or both in the
clinic and the patient’s home. All but Yorke’s inter-
vention were delivered individually. Only the service
described in Yorke’s study integrated one group
meeting as part of the intervention.26
The duration of the intervention delivered by the
breathlessness services ranged from 220 to 12 weeks26
with a median of 6 weeks. The Cambridge Breath-
lessness Intervention Service (CBIS; evaluated by
Farquhar et al. in a pragmatic waiting list trial) pro-
vided the same service to patients with advanced
malignant and non-malignant disease but varied the
duration of the waiting time for the intervention in the
study. People with advanced cancer were seen after 2
weeks and those with non-malignant disease waited 4
weeks.20–22
Services were provided by various professions
either alone or most often in varying combinations.
Bredin’s clinic was run by specialist nurses alone19; in
Johnson’s study, the type of professional (e.g. nurse,
physiotherapist, occupational therapist) providing the
standardized intervention was not stipulated25; in
Yorke’s study, it was either nurses or physiotherapists
or complementary therapists trained in the interven-
tion.26 In Higginson’s BSS, consultants in palliative
medicine jointly with consultants in respiratory
medicine were the main service providers in close
collaboration with physiotherapists or occupational
therapists, and in CBIS, the service was mainly
provided by allied health professionals backed up by
consultants in palliative medicine.17,20,22 In CBIS, the
lead for the intervention varied depending on
the underlying condition with the palliative medicine
consultant being the lead in cancer patients and the
clinical specialist occupational therapist or the clini-
cal specialist physiotherapist taking lead in non-can-
cer patients.21
Recipients of the services were patients with
advanced malignant and non-malignant disease all
suffering from breathlessness. Bredin’s and Yorke’s
services were targeted at patients with primary lung
cancer,19,26 Johnson’s intervention to patients with
intrathoracic malignancy,25 CBIS sees patients with
any diagnosis – for the purpose of evaluating the ser-
vice there were two protocols as previously dis-
cussed.20,22 Higginson et al. evaluated the
effectiveness of BSS based on the CBIS protocol
offering the service to all patients with advanced dis-
ease irrespective of the underlying condition.17
Details are shown in Table 1.
Targeted domains in the breathlessness services
Many components of the interventions used in the
services can be related to the breathing–thinking–
functioning model (see Table 2).
The breathing dimensionwas targeted by breathing
control exercises in all services. Patients were intro-
duced to a handheld fan in the CBIS and BSS.17,20,22
Airways clearance techniques were taught in Farqu-
har’s and Higginson’s studies,17,20,22 and cough mini-
mization techniques in Higginson’s and Yorke’s
services.17,26
The thinking dimension was targeted by distraction
techniques,19 psychological support20,22 and anxiety
management.17,20,22,24–26
The functioning dimension was targeted by an indi-
vidualized exercise plan,20,22 a home programme of
exercise delivered by a personalized sheet with a
DVD17 or advice on activity management and energy
conservation strategies.
Initial assessment of the individual situation of the
patient was part of the services evaluated by Bredin
et al., Farquhar et al. and Higginson et al.17,19,20,22 but
not in the Breathing training described by Johnson
and the Respiratory Distress Symptom Intervention
developed by Yorke.24–26
Services also provided interventions that affect
more than one dimension of the breathing–thinking–
functioning model, for example, relaxation
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techniques20,22,24,25 or acupressure,26 and recognized
that although one ‘vicious circle’ may be dominant,
all are likely to operate in one individual.
All services had additional educational and coun-
selling elements. Educational elements included
explanation and reassurance, advice on nutrition and
hydration20,22 or sleep hygiene.20,21,26 Written infor-
mation was provided in the form of breathlessness
packs or information fact sheets.17,20,22,24,26 CBIS
also provided online educational films and relaxation
tracks (www.cuh.org.uk/breathlessness-intervention-
service-bis/resources).
Counselling included general advice to patients
and families on breathlessness management, develop-
ment of a crisis plan for management of exacerba-
tions, other symptom burden, psychosocial and
spiritual issues and carer support.
CBIS and BSS also included medical assessment
with review of the underlying disease and change of
medication, if necessary.17,20 These services also
referred patients to other services or medical special-
ities if further help or support was needed.
Munich Breathlessness Service
The MBS started to operate in 2014 in the Munich
University Hospital alongside a single-blinded fast-
track RCT evaluating its effectiveness. The MBS
aims to optimize management of breathlessness in
patients with advanced malignant and non-
malignant disease. The development of the breath-
lessness service was based on experiences of the
London BSS17 and a qualitative study of patients’,
carers’ and clinicians’ experiences and needs
(unpublished data).
Patients are included if they are affected by breath-
lessness on exertion or at rest due to any advanced
life-limiting and progressive disease. Suitable patients
are troubled by breathlessness despite optimally med-
ical treatment of their underlying condition and must
be able to engage in a multi-faceted intervention pro-
gramme including physiotherapy and self-
management (in a cognitive and functional manner).
Carers are invited to join at all visits; active partici-
pation is encouraged.
The service is provided by a multi-professional
team, comprising palliative care consultants,
respiratory physicians, physiotherapists and an
administrator.
If the patient has been referred by his/her practice-
based respiratory physician, the last contact with this
clinician should have been within a few months of
inclusion in the study and their disease should be
stable. The referring respiratory physician will pro-
vide a referral letter and recent lung function tests and
in this case the patient will not need to be seen by the
respiratory physician of the MBS. The team also has
access to psychologists, social workers and nurses if
necessary.
The service is based within an outpatient clinic
with patients attending twice within a 6-week period.
In between these visits, patients have four weekly
sessions with a community-based physiotherapist.
The service administrator arranges clinic visits
making it as easy as possible for patients. Letters from
treating physician(s) are reviewed before the visit.
Patients provide a list of current medication, fill in a
symptom-oriented assessment of palliative care needs
and have a lung function test with a portable diagnos-
tic spirometer shortly before the visit.
During their first visit, patients will receive
detailed assessment of their breathlessness and the
burden caused by breathlessness in the context of the
underlying disease, relevant symptoms beyond
breathlessness, psychosocial issues and carer burden.
Palliative care specialists will optimize integrated
management jointly with practice or hospital-based
respiratory specialists comprising (i) non-
pharmacological and pharmacological measures, (ii)
help with day-to-day coping with breathlessness and
acute crisis management and (iii) support for carers.
An individual management plan is developed with the
patient based on the ‘breathing–thinking–functioning
model’. Written material, selected according to the
individual’s needs, is given out to patients during the
first visit. A written management plan including an
information booklet, a handheld fan, a relaxation CD
and a mantra printed on variable sized laminated
paper is also provided. A range of additional service
components are added if needed: at the first visit at the
clinic, patients can be seen by a member of the
respiratory medicine team in addition to palliative
medicine, depending on the management of the
underlying disease. Patients are offered the opportu-
nity to see other professionals (psychologists, social
workers) if needed in addition to physiotherapy. Writ-
ten reports will be sent to patients and general practi-
tioners. Physiotherapists and referrers are copied in.
The physiotherapist will focus on positioning,
breathing techniques, exercise and pacing and fatigue
management. Physiotherapists working with MBS
patients have received a specialized training in
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treating patients with breathlessness and those with
lung disease. After the initial visit in the clinic, they
are informed about the patient’s goals by the MBS
consultant. Physiotherapy sessions last for 60 min-
utes. Individual treatment goals are documented in
an assessment sheet which is sent to the MBS consul-
tant before the second clinic visit of the patient.
At the second clinic visit, patients and the palliative
care consultant jointly review the management plan.
This includes the use of the handheld fan and the
physiotherapy sessions, reassessment of needs and
information about advance care planning. Further
steps may include additional physiotherapy, prescrip-
tion of drugs and equipment or continued links to the
regular palliative care outpatient clinic.
In summary, treatment at the MBS follows a struc-
tured approach and is short term. Within its standard
elements, it is tailored to each individual patient,
allowing for variation of the therapeutic approach,
treatment elements and recommendations. Within the
course of the treatment period, clinician contact is
increased (by telephone) or other professionals join
the team, if needed. Patients receive advance infor-
mation about the aims of the treatment, care coordi-
nation during its course and written reviews.
For an overview of the intervention, please see the
intervention plan as delineated in Table 3.
Since 2014, 120 patients have been treated in the
MBS. As the accompanying study includes a fast-
track design, all patients have access to the service
(either immediately or after an 8-week waiting
period). About two-thirds of the patients suffer from
COPD, 10% have pulmonary hypertension, 7.5%
have ILD and 6% have malignant disease or CHF,
respectively. Referrals come via healthcare providers
(15%), media (75%, via newspaper articles, adverts,
leaflets) and social contacts (10%; e.g. self-help
groups, family, friends).
Patients’ feedback has identified the following as
the most valuable aspects of the MBS approach to care:
 Communication with consultant ‘heartening
and reassuring’
 Honest talk, no euphemisms
 Plenty of time for ‘finding out things you never
come across otherwise’
 Taking away the fear (about living with the
disease)
 Offering help with what matters most (emer-
gency planning; palliative care services as new
source of support)
 Practical exercises from physiotherapy, addres-
sing individual restrictions such as climbing
stairs
 Positive experience of self-efficiency and that
daily training makes a difference
 Carer support: ‘it’s mainly psychological sup-
port to cope with the disease’ – helped greatly
There are also several challenges in the service
provision. Patients’ trajectories are highly susceptible
to adverse health events during the course of the treat-
ment with just about half completing treatment within
6 weeks and about one-third needing more than 6
weeks. About 12% dropped out of the intervention.
Also, patients find it difficult to manage weekly visits
for several continuous weeks either because of health
issues or because they are still very active. When
patients rely on public transport, some find the travel-
ling to/from the clinic burdensome.
Physiotherapy is delivered in the community by
registered physiotherapists who specialize in the treat-
ment of patients with lung disease and breathlessness,
focusing on self-management strategies. Some
patients have their own treating physiotherapist and
do not want to change providers for the short-term
intervention. This is challenging as they might not get
the same specialist advice and support.
As the concept of a specialist breathlessness ser-
vice is new in Germany, many physicians are quite
sceptical about the concept fearing to lose ‘their’
patients or that they are providing this sort of care
already. Some discourage the patients from accepting
care, implying that the patients don’t need palliative
care (yet) or that they are taking the place from some-
one in more need.
Discussion
Breathlessness services for patients with advanced
disease are a rather new concept emerging over the
last 10–15 years. Various service models have been
developed, mainly in the United Kingdom, and eval-
uated in several studies. Overall, studies demonstrate
positive results, indicating that these services have a
positive impact on patients with breathlessness.
Breathlessness services combine two important
aspects for patients with advanced disease. The ser-
vices aim to improve the management of breathless-
ness and also provide early access to palliative care.
Management of these patients is normally guided by
treatment of the underlying disease with the
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assumption that symptoms such as breathlessness
automatically improve. Specific knowledge about the
management of breathlessness and especially the non-
pharmacological options is rather scarce, and patients
describe difficulty in accessing services and the help-
lessness of professionals in dealing with the symp-
tom.27 However, a number of treatment options for
breathlessness have been evaluated and tested over
recent years, and the overall understanding of the
symptom has improved.28 The breathlessness services
focus on the symptom rather than the disease and
provide expert knowledge and skills from a multi-
professional team focusing mainly on non-
pharmacological measures.15 There seem to be two
different models. First, those which are physician led,
also including individual assessment, medical review
and developing individualized management
plans.17,20,22 These physician-led models have mainly
been developed by two groups in Cambridge and
London in the United Kingdom, working closely
together. Physician-led models differ in respect to the
intervention being interdisciplinary, that is, palliative
and respiratory medicine consultants working closely
together, such as in BSS, or palliative medicine only as
in CBIS. Another difference between services is that
some provide predefined sessions delivered by nurses
or therapists to the patients either individually or in a
group setting.24–26 Bredin’s model, one of the first in
its kind, seems to combine parts of both.19 It is nurse
led but includes individual assessment and goal setting.
Early access to palliative care is meanwhile widely
accepted in patients with cancer.29 However, patients
with non-malignant disease such as COPD or pulmon-
ary hypertension or ILD, who have proven palliative
care needs, find it hard to access palliative care at any
stage but particularly early in the disease trajectory.
Breathlessness is a burdensome and distressing
symptom predominantly in advanced respiratory
Table 3. The Munich Breathlessness Service.
Time Type of contact Professional Action
Week 1 Clinic visit Consultant palliative medicine;
consultant respiratory
medicine
Palliative medicine:
–assessment of intensity and quality of shortness of
breath, including emotional stress of patient and carer
–review of symptom burden (IPOS)
–information about non-pharmacological measures for
symptom control
–development of dyspnoea plan for emergency
situations
–if needed: referral to social worker or psychologist,
increased clinician contact (by telephone)
Respiratory medicine (either external or internal)
–assessment of cause of shortness of breath
–review of treatment plan
–review of results from functional tests and physical
examinations
Letter Consultant palliative medicine Summary of assessment and recommendations,
treatment plan; copy to GP/referrers
Weeks 2–5 Physiotherapy
visits
Physiotherapy –exercise and positions to facilitate breathing
–breathing techniques
–exercise plan
–assessment of need for medical aids
Week 6 Clinic visit Consultant palliative medicine –assessment of intensity and quality of shortness of
breath, including emotional stress of patient and carer
–review of symptom burden (IPOS)
–review of treatment plan (including medication)
–if needed: referral to medical specialists
Letter Consultant palliative medicine Summary of progress in shortness of breath
management, further recommendations; copy to GP/
referrers
GP: general practitioner; IPOS: Integrated Palliative care Outcome Scale
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disease and occurs not only towards the end of life but
early in the disease trajectory. It is frequently accom-
panied by other burdensome symptoms, and patients
and families have other palliative care needs. There-
fore, providing a service tailored to the needs of
patients with breathlessness due to advanced disease
by palliative care professionals not only relieves their
symptom burden but also addresses other potential
palliative care needs and allows early access to pal-
liative care. Nevertheless, patients who are near death
will be directly referred to palliative care services.
The services tested in RCTs are all based in the
United Kingdom. The MBS builds on the United
Kingdom experience and is a first attempt of such a
service with adaptation to another healthcare system
than the NHS. In the German healthcare system, com-
bining a hospital-based outpatient clinic with
community-based services is challenging as there is
normally only little crossover between these settings.
Also, in Germany, outpatient care is mainly provided
by self-employed doctors, either family doctors or
specialists. Thus, many respiratory physicians provide
the main care for patients with lung disease from
community-based practices. They have to get adapted
to the idea that a palliative care service is offered as a
short-term intervention to support them in the care of
breathless patients. Some of the hesitance of respira-
tory physicians is reflected in the high self-referral
rates to the service of patients who came across the
service by adverts and leaflets. However, this is
changing over time, and physician referral is increas-
ing recently.
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